copanlisib
Sign in to saveAlso known as BAY 80-6946, BAY80-6946
Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
~3 min read
Encyclopedic overview
8 sectionsContents
- Adverse effects
- Mechanism of action
- History
- Clinical trials
- Society and culture
- Legal status
- References
- Further reading
Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
In November 2023, Bayer announced that it was withdrawing copanlisib from the US market.
Excerpted from Wikipedia’s “copanlisib” article, available under the CC BY-SA 4.0 licence.